FacebookTwitterGoogle+RedditEmail

Patient Front Groups Loot Medicare Dollars for Big Pharma

by MARTHA ROSENBERG

The Obama administration is finally addressing the expensive, dangerous and usually unnecessary psychiatric drugs that are footed by taxpayers in federal entitlement programs. It has proposed that insurers may limit Medicare coverage of certain classes of drugs that include Wellbutrin, Paxil and Prozac for depression and Abilify and Seroquel for schizophrenia.

How expensive are these drugs? 100 middle dose pills of the widely marketed Abilify cost as much as $1,644. 100 pills of Geodon are $958, Invega, $1,789, Risperdal, $953, Seroquel, $2,000 and Zyprexa, $1,680, if the brand name drugs are used, which drug company  lobbyists hope. Thanks to their lobbying, insurers have to pay “all or substantially all” of such depression and schizophrenia drug costs because the drugs enjoy “protected status” in the Medicare program. Such protected pills account for as much as 33 percent of total outpatient drug spending under Part D of Medicare, says the New York Times.

Not surprisingly, Big Pharma and its patient front groups are livid that the heisting of US taxpayers dollars could be curtailed. Abilify alone has earned over $4 billion a year! “The proposal undermines a key protection for some of the sickest, most vulnerable Medicare beneficiaries,” said Andrew Sperling, a lobbyist at the National Alliance on Mental Illness (NAMI) which is fighting the Obama proposal.

As much as 75 percent of NAMI’s donations come from drug companies says the New York Times and it has been investigated by Congress. Portraying itself as “patients,” NAMI also successfully fights states’ efforts to limit use of the most pricey Medicaid psychiatric drugs, in parallel lobbying. “Some of these medicines routinely top the list of the most expensive drugs that states buy for their poorest patients,” says the Times. NAMI is “hugely influential in many state capitols,” it adds.

The heart of Big Pharma and NAMI lobbying is making sure expensive drugs are on Medicare and Medicaid formularies and that doctors prescribe them first–before and instead of lower priced drugs. The expensive-drugs-first marketing is couched as “patient choice” or another “treatment option” by Pharma lobbyists as if there’s no difference between a $45 prescription and $450 prescription. Antipsychotic drugs work in different ways in the body explains Sperling and “You get much better outcomes when a doctor can work with patients to figure out which medications will work best for them.” Ka-ching.

The problem is newer, more expensive drugs are not necessarily better than older, less expensive drugs and they are often more dangerous. One chilling example is an estimated 15,000 elderly people die in nursing homes a year from inappropriately given antipsychotic medications, according to FDA drug reviewer David Graham, MD.  Pharma is aware of the profiteering and “laughing all the way to the bank,” Graham speculated.

Antipsychotics like Seroquel carry warnings that they cause death in elderly people who have dementia but are nevertheless in wide use in many geriatric, federally-supported facilities. So much for NAMI’s concern for “the sickest, most vulnerable Medicare beneficiaries.”

NAMI is not the only group to play on the public’s heart strings to keep drug revenues flowing. Pharma’s aggressive opioid lobby says patients with legitimate pain will suffer if drugs like Oxycontin, killing 17,000 Americans a year, are regulated. Similarly, if Abilify and Seroquel are regulated within Medicare, someone will suffer–Big Pharma.

Martha Rosenberg is an investigative health reporter. She is the author of  Born With A Junk Food Deficiency: How Flaks, Quacks and Hacks Pimp The Public Health (Prometheus).

 

 

 

 

 

Martha Rosenberg is an investigative health reporter. She is the author of  Born With A Junk Food Deficiency: How Flaks, Quacks and Hacks Pimp The Public Health (Prometheus).

More articles by:

CounterPunch Magazine

minimag-edit

bernie-the-sandernistas-cover-344x550

zen economics

May 25, 2017
Jennifer Matsui
The Rise of the Alt-Center
Michael Hudson
Another Housing Bubble?
Robert Fisk
Trump Meets the New Leader of the Secular World, Pope Francis
John Laforge
Draft Treaty Banning Nuclear Weapons Unveiled
Benjamin Dangl
Trump’s Budget Expands War on the Backs of America’s Poor
Alice Donovan
US-Led Air Strikes Killed Record Number of Civilians in Syria
Andrew Moss
The Meaning of Trump’s Wall
Leslie Scott
Trump in the Middle East: New Ideas, Old Politics
George Wuerthner
Environmental Groups as Climate Deniers
Pauline Murphy
The Irish Dead: Fighting Fascism in Spain, 1937
Brian Trautman
Veterans on the March
Eric Sommer
Trumps Attack on Social Spending Escalates Long-term Massive Robbery of American Work
Binoy Kampmark
Twenty-Seven Hours: Donald Trump in Israel
Christian Hillegas
Trump’s Islamophobia: the Persistence of Orientalism in Western Rhetoric and Media
Michael J. Sainato
Russiagate: Clintonites Spread the Weiner Conspiracy
Walter Clemens
What the President Could Learn from Our Shih-Tzu Eddie
May 24, 2017
Paul Street
Beyond Neoliberal Identity Politics
Daniel Read
Powder Keg: Manchester Terror Attack Could Lead to Yet Another Resurgence in Nationalist Hate
Robert Fisk
When Peace is a Commodity: Trump in the Middle East
Kenneth Surin
The UK’s Epochal Election
Jeff Berg
Lessons From a Modern Greek Tragedy
Steve Cooper
A Concrete Agenda for Progressives
Michael McKinley
Australia-as-Concierge: the Need for a Change of Occupation
William Hawes
Where Are Your Minds? An Open Letter to Thomas de Maiziere and the CDU
Steve Early
“Corporate Free” Candidates Move Up
Fariborz Saremi
Presidential Elections in Iran and the Outcomes
Dan Bacher
The Dark Heart of California’s Water Politics
Alessandra Bajec
Never Ending Injustice for Pinar Selek
Rob Seimetz
Death By Demigod
Jesse Jackson
Venezuela Needs Helping Hand, Not a Hammer Blow 
Binoy Kampmark
Return to Realpolitik: Trump in Saudi Arabia
Vern Loomis
The NRA: the Dragon in Our Midst
May 23, 2017
John Wight
Manchester Attacks: What Price Hypocrisy?
Patrick Cockburn
A Gathering of Autocrats: Trump Puts US on Sunni Muslim Side of Bitter Sectarian War with Shias
Shamus Cooke
Can Trump Salvage His Presidency in Syria’s War?
Thomas S. Harrington
“Risk”: a Sad Comedown for Laura Poitras
Josh White
Towards the Corbyn Doctrine
Mike Whitney
Rosenstein and Mueller: the Regime Change Tag-Team
Jan Oberg
Trump in Riyadh: an Arab NATO Against Syria and Iran
Susan Babbitt
The Most Dangerous Spy You’ve Never Heard Of: Ana Belén Montes
Rannie Amiri
Al-Awamiya: City of Resistance
Dimitris Konstantakopoulos
The European Left and the Greek Tragedy
Laura Leigh
This Land is Your Land, Except If You’re a Wild Horse Advocate
Hervé Kempf
Macron, Old World President
Michael J. Sainato
Devos Takes Out Her Hatchet
FacebookTwitterGoogle+RedditEmail